Saturday 17 October 2026
Export ACXP’s income statement to Excel — free account
Acurx Pharmaceuticals, Inc.
ACXP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.0% and free cash flow fell 2.36%, each against the same quarter a year earlier.
1.10
0.07
−5.98%
Follow ACXP
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 74.20 | 46.60 | 23.40 | 14.40 | 2.49 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 174.80 | 97.80 | 176.40 | 105.60 | 25.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 3 | 4 | 4 | 4 | 4 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | (6) | (5) | (13) | (12) | (15) | (14) | (8) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (6) | (5) | (13) | (12) | (15) | (14) | (8) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (24.71) | (14.86) | (29.80) | (22.40) | (23.00) | (17.40) | (5.32) | |||||
| Cash flow | — | — | — | (16.60) | (10.83) | (11.75) | (13.95) | (15.47) | (12.85) | (4.53) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (16.60) | (10.83) | (11.75) | (13.95) | (15.47) | (12.85) | (4.53) | |||||
| Book value | — | — | — | 3.41 | 8.73 | 29.08 | 13.53 | 7.37 | 0.76 | 3.52 | |||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (3) | (5) | (8) | (10) | (10) | (7) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (4) | (3) | (5) | (8) | (10) | (10) | (7) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 3 | 12 | 7 | 5 | 1 | 5 | ||||
| Total debt | — | — | — | — | 0 | — | — | — | — | — | |||||
| Net debt | — | — | — | (2) | (3) | (13) | (9) | (7) | (4) | (8) | |||||
| Shareholders’ equity | — | — | — | 1 | 3 | 12 | 7 | 5 | 1 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (468.62) | (159.85) | (154.72) | (106.87) | (170.64) | (243.85) | (137.98) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (336.86) | (261.25) | (168.71) | (122.61) | (243.33) | (534.03) | (270.80) | |||||
Negative figures in brackets.
Charts ten years each
Acurx Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AIM AIM ImmunoTech Inc. | $6.8M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.7M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | Compare |
| ACXP Acurx Pharmaceuticals, Inc. | $6.5M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | |
| TCRT Alaunos Therapeutics, Inc. | $6.4M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | +57.20% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EVGN Evogene Ltd. | $6.3M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| LEXX Lexaria Bioscience Corp. | $6.3M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ENVB Enveric Biosciences, Inc. | $6.2M | — (loss-making) | — (loss-making) | −7.28% (below 0%: shrinking) | n/m | −29.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $6.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $6.4M | — | — | −35.02% | — | −3.89% | 80.77% | 0.00% |
Acurx Pharmaceuticals, Inc. (ACXP) key facts
- Acurx Pharmaceuticals, Inc. (ACXP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ACXP traded at $1.10, a market capitalization of $6.5 million.
- Return on equity was −270.8% and debt-to-equity 0.00.